Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis: Outcomes in 102 patients

Muscle and Nerve

Volumn 41, Issue 5, 2010, Pages 593-598

  Hehir, Michael K ^a   Burns, Ted M ^a   Alpers, Joshua ^b   Conaway, Mark R ^a   Sawa, Michael ^b   Sanders, Donald B ^b  

^a UNIVERSITY OF VIRGINIA   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Autoimmune disease; Immunosuppressants; Myasthenia gravis; Mycophenolate mofetiltreatment

Indexed keywords

CHOLINERGIC RECEPTOR ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER PLUS PREDNISONE; PREDNISONE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MANUAL MUSCLE TEST; MONOTHERAPY; MYASTHENIA GRAVIS; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OUTCOME ASSESSMENT; PATIENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AUTOANTIBODIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FEMALE; HUMANS; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; MYCOPHENOLIC ACID; OUTCOME ASSESSMENT (HEALTH CARE); PREDNISONE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, CHOLINERGIC; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77951288989     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.21640     Document Type: Article

References (26)

1. Allison AC, Eugui EM. Purine metabolism and immunosuppressive effects of mycophenolate mofetil. Clin Transplant 1996;10:77-84.
2. Schneider-Gold C, Hartung HP, Gold R. Mycophenolate mofetil and tacrolimus: new therapeutic options in neuroimmunological diseases. Muscle Nerve 2006;34:284-291.
3. Hauser RA, Malek AR, Rosen R. Successful treatment of a patient with severe refractory myasthenia gravis using mycophenolate mofetil. Neurology 1998;51:912-913.
4. Chaudhry V, Cornblath DR, Griffin JW, O'Brien R, Drachman DB. Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases. Neurology 2001;56:94-96.
5. Ciafaloni E, Massey JM, Tucker-Lipscomb B, Sanders DB. Mycophenolate mofetil for myasthenia gravis: an open label pilot study. Neurology 2001;56:97-99.
6. Ciafaloni E. Mycophenolate mofetil and myasthenia gravis. Lupus 2005;14(suppl):S46-S49.
7. Cos L, Mankodi AK, Tawil R, Thornton CA. Mycophenolate mofetil (MyM) is safe and well-tolerated in myasthenia gravis (MG). Neurology 2000;54(suppl 3):A137.
8. Meriggioli MN, Rowin J, Richman JG, Leurgans S. Mycophenolate mofetil for myasthenia gravis: a double-blind, placebo-controlled pilot study. Ann NY Acad Sci 2003;998:494-499.
9. Meriggioli MN, Ciafaloni E, Al-Hayek KA, Rowin J, Tucker-Lipscomb B, Massey JM, et al. Mycophenolate mofetil of myasthenia gravis: an analysis of efficacy, safety, and tolerability. Neurology 2003;61:1438-1440.
10. The Muscle Study Group. A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology 2008;71:394-399.
11. Sanders DB, Hart IK, Mantegazza R, et al. An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology 2008;71:400-406.
12. Sanders DB, Siddiqi ZA. Lessons from two trials of mycophenolate mofetil in myasthenia gravis. Ann NY Acad Sci 2008;1132:249-253.
13. Phan C, Sanders DB, Siddiqi ZA. Mycophenolate mofetil in myasthenia gravis: the unanswered question. Expert Opin Pharmacother 2008;9:2545-2551.
14. Sanders DB, Tucker-Lipscomb B, Massey JM. A simple manual muscle test for myasthenia gravis: validation and comparison with the QMG score. Ann NY Acad Sci 2003;998:440-444.
15. Jaretzki A, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, et al. Myasthenia gravis. Recommendations for clinical research standards. Neurology 2000;55:16-23.
16. Palace J, Newsom-Davis J, Lecky B. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Neurology 1998;50:1778-1783.
17. Tindall RS, Phillips JT, Rollins JA, Wells L, Hall K. A clinical therapeutic trial of cyclosporine in myasthenia gravis. Ann NY Acad Sci 1993;681:539-551.
18. Grob D, Arsura EL, Brunner NG, Namba T. The course of myasthenia gravis and therapies affecting outcome. Ann NY Acad Sci 1987;505:472-499.
19. Grob D, Brunner NG, Namba T. The natural course of myasthenia gravis and effect of therapeutic measures. Ann NY Acad Sci 1981;377:652-669.
20. Pascuzzi RM, Coslett HB, Johns TR. Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients. Ann Neurol 1984;15:291-298.
21. Mantegazza R, Beghi E, Pareyson D, Antozzi C, Peluchetti D, et al. A multicentre follow-up study of 1152 patients with myasthenia gravis in Italy. J Neurol 1990;237:339-344.
22. Beghi E, Antozzi C, Batocchi AP, et al. Prognosis of myasthenia gravis: a multicenter follow-up study of 844 patients. J Neurol Sci 1991;106:213-220.
23. Haley EC. Registries: they're not just for weddings anymore. Neurology 2008;70:1508-1509.
24. Sanders DB, Massey JM, Juel VC. MuSK-antibody MG: response to various treatments in 32 patients. Ann NY Acad Sci 2008;1132:382.
25. Zhou L, McConville J, Chaudhry V, Adams RN, Skolasky RL, Vincent A, et al. Clinical comparison of muscle-specific tyrosine kinase (MuSK) antibody-positive and negative myasthenic patients. Muscle Nerve 2004;30:55-60.
26. Bhanushali MJ, Wuu J, Benatar M. Treatment of ocular symptoms in myasthenia gravis. Neurology 2008;71:1335-1341.